Compositions and methods for the prevention and control of insulin-induced hypoglycemia
First Claim
Patent Images
1. A system for reducing the risk of hypoglycemia, said system comprising:
- a syringe for administration of glucagon to a subject; and
a slow release dosage of glucagon that provides 2 to 16 ng of glucagon per kilogram of subject weight per minute to a subject, for a period of at least 1 hour, wherein said glucagon is administered subcutaneously.
0 Assignments
0 Petitions
Accused Products
Abstract
Pharmaceutical compositions comprising glucagon can be administered to control and treat diabetes while reducing or eliminating the risk of insulin-induced hypoglycemia. Also provided are methods of administering glucagon so as to reduce the risk of inducing hypoglycemia.
129 Citations
20 Claims
-
1. A system for reducing the risk of hypoglycemia, said system comprising:
-
a syringe for administration of glucagon to a subject; and a slow release dosage of glucagon that provides 2 to 16 ng of glucagon per kilogram of subject weight per minute to a subject, for a period of at least 1 hour, wherein said glucagon is administered subcutaneously. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
-
- 15. A depot glucagon formulation comprising glucagon, wherein the depot glucagon formulation provides glucagon to a subject at a rate between 2 to 16 ng per kg of subject weight per minute when administered subcutaneously to the subject, wherein the subject weighs 50 to 100 kg.
-
17. A pharmaceutical composition comprising:
-
insulin in an amount effective for the control of diabetes; and glucagon in an amount effective for reducing the risk of hypoglycemia in a human or other mammal, wherein said insulin is present in said composition at a ratio of insulin to glucagon of about 1 unit of insulin to between more than 0.02 milliunits up to 200 milliunits of glucagon, and wherein the glucagon is part of a slow release dosage that provides 2 to 16 ng of glucagon per kilogram of subject weight per minute to the subject wherein said glucagon is administered subcutaneously. - View Dependent Claims (18)
-
-
19. A method of treating diabetes in a human or other mammal without inducing hypoglycemia, said method comprising:
- administering insulin in an amount therapeutically effective for the control of diabetes, wherein said insulin is in an amount between 0.5 and 20 units of insulin; and
administering glucagon in time and an amount therapeutically effective for reducing the risk of hypoglycemia, wherein said glucagon is administered subcutaneously, and wherein the amount of glucagon administered is 2 to 16 ng per kilogram of subject weight per minute to the subject.
- administering insulin in an amount therapeutically effective for the control of diabetes, wherein said insulin is in an amount between 0.5 and 20 units of insulin; and
-
20. A kit for the administration of glucagon and insulin in amounts to reduce the risk of hypoglycemia, said kit comprising:
- glucagon;
insulin, wherein said glucagon and insulin are in a ratio of 1-20 units of insulin to 32-480 milliunits of glucagon;
a means for administering glucagon subcutaneously; and
instructions for the administration of insulin and glucagon so that the glucagon reduces the risk of a hypoglycemic event by providing 2 to 16 ng of glucagon per kilogram of subject weight per minute to the subject.
- glucagon;
Specification